ReviewCurrent neuropharmacology2017
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
Review in Current neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05015595 (Memantine for Refractory OCD Patients), which is not on this map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Memantine Augmentation in Obsessive-Compulsive Disorder: A Systematic Review and Meta-analysis.CNS drugs · 2026Pooled it
- Memantine for the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis.BMC psychiatry · 2026Pooled it
- Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2021Pooled it
- Mechanisms of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: Cortico-Striatal Circuitry, Glutamatergic Dysregulation, and Neuroplastic Constraints.Molecular neurobiology · 2026Review
- Clinical symptoms and cognitive functioning following adjunctive N-acetylcysteine in obsessive-compulsive disorder: a double-blind, placebo-controlled trial.Communications medicine · 2026Article
- Biological, Psychosocial, and Microbial Determinants of Childhood-Onset Obsessive-Compulsive Disorder: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Potential biomarkers and therapeutic targets for obsessive compulsive disorder: Evidences from clinical studies.Biochemia medica · 2024Review
- Reduced Expression of the Htr2a, Grin1, and Bdnf Genes and Cognitive Inflexibility in a Model of High Compulsive Rats.Molecular neurobiology · 2023Article
- Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction.Brain and behavior · 2023Review
- Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial.JMIR research protocols · 2023Article
- The development of compulsive coping behaviour is associated with a downregulation of Arc in a Locus Coeruleus neuronal ensemble.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Differential Neurobiological Markers in Phenotype-stratified Rats Modeling High or Low Vulnerability to Compulsive Behavior: A Narrative Review.Current neuropharmacology · 2023Review
- The rat Lux Actuating Search Task (LAST) and effects of sleep deprivation on task reversal performance.Neurobiology of sleep and circadian rhythms · 2022Article
- Neurogenetics of Dynamic Connectivity Patterns Associated With Obsessive-Compulsive Symptoms in Healthy Children.Biological psychiatry global open science · 2022Article
- WNT/β-catenin pathway and circadian rhythms in obsessive-compulsive disorder.Neural regeneration research · 2022Review
- Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial.Contemporary clinical trials communications · 2022Article
- Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway.Molecular psychiatry · 2022Review
- Genetics of obsessive-compulsive disorder.Psychological medicine · 2021Review
- Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?World journal of psychiatry · 2021Review
- Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.Brain sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveObsessive-compulsive disorder (OCD) is a mental disease commonly associated with severe distress and impairment of social functioning. Serotonin reuptake inhibitors and/or cognitive behavioural therapy are the therapy of choice, however up to 40% of patients do not respond to treatment. Glutamatergic signalling has also been implicated in OCD. The aim of the current study was to review the clinical evidence for therapeutic utility of glutamate-modulating drugs as an augmentation or monotherapy in OCD patients.
methodsWe conducted a search of the MEDLINE database for clinical studies evaluating the effect of glutamate-modulating drugs in OCD.
resultsMemantine is the compound most consistently showing a positive effect as an augmentation therapy in OCD. Anti-convulsant drugs (lamotrigine, topiramate) and riluzole may also provide therapeutic benefit to some OCD patients. Finally, ketamine may be of interest due to its potential for a rapid onset of action.
conclusionFurther randomized placebo-controlled trials in larger study populations are necessary in order to draw definitive conclusions on the utility of glutamate-modulating drugs in OCD. Furthermore, genetic and epigenetic factors, clinical symptoms and subtypes predicting treatment response to glutamate-modulating drugs need to be investigated systematically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.